Toxicologic pathologists employ animal models to help understand and predict responses in humans, focusing on toxic and pharmacologic effects in particular. Application of statistics to data sets from toxicologic pathology studies involves hypothesis testing, model fitting, and reduction of dimensionality. This chapter reviews statistical approaches to processing and analyzing data (i.e., descriptive statistics, confidence intervals, parametric and nonparametric methods, multiple range tests, handling of outliers), specific applications (e.g., Bayesian statistics), and other experimental design and statistical methods.

Toxicology can be defined as that branch of science that deals with poisons, and a poison can be defined as any substance that causes a harmful effect when administered, either by accident or design, to a living organism. In short, it is the study of toxic kinetics and toxic dynamic. Poison is a quantitative concept, almost any substance being harmful at some doses but, at the same time, being without harmful effect at some lower dose. Between these two limits there is a range of possible effects, from subtle long-term chronic toxicity to immediate lethality. Vinyl chloride may be taken as an example. It is a potent hepatotoxic at high doses, a carcinogen with a long latent period at lower doses, and apparently without effect at very low doses. The measurement of toxicity is also complex. Toxicity may be acute or chronic, and may vary from one organ to another as well as with age, genetics, gender, diet, physiological condition, or the health status of the organism. Exposure of humans and other organisms to toxicants may result from many activities: intentional ingestion, occupational exposure, environmental exposure, as well as accidental and intentional (suicidal or homicidal) poisoning. The toxicity of a particular compound may vary with the portal of entry into the body, whether through the alimentary canal, the lungs, or the skin. The initial approach to a person who has been poisoned should be to assess the airway, breathing, and circulation, and to take a thorough history. Less than 1 per cent of poisonings are fatal; therefore, management in most cases is supportive unless a specific antidote is available. Treatment for poisoning depends on the type of exposure (e.g., ingestion, inhalation), the specific toxin (poisonous substance), and the severity of the person's condition. Childhood poisoning that involves a foreign object (e.g., small toy, battery) may require surgery to remove the object. This review article gives you an overall view on toxicity, its principles, management and treatment.

The twenty-rst century is poised to be a time of biological wonder. The knotty problems of centuries, even millennia, now can be solved in periods so short and for costs so minor that the promise of real-time personalized medicine based on a patient's own genomic code and protein complement seems poised to become a fact in our lifetimes. A Brave New World is upon us, indeed.

As with all specialized scientic endeavors, the elds of developmental biology and developmental pathology have built long lists of jargon to describe the essential structures, functions, and processes that are encountered in young animals. Individuals who engage in the acquisition, analysis, and interpretation of normal features and developmental lesions must have a ready command of the terminology required to ensure that information is communicated precisely to persons who seek to gain insights from developmental pathology studies. Correct terminology is also essential to permit a proper statistical analysis; calculations performed using a nonspecic term (e.g., neural tube defect) will require a different analysis relative to calculations made using classes dened by more discrete terms (anencephaly, exencephaly, encephalocele, etc.). The terms in this chapter have been drawn from multiple sources, including medical dictionaries1,5 and published committee reports regarding preferred nomenclature.4,6 Mouse developmental pathology researchers also should seek to glean new terms that they encounter in the scientic literature.

This review compares the biological and physiological function of Sigma receptors [σRs] and their potential therapeutic roles. Sigma receptors are widespread in the central nervous system and across multiple peripheral tissues. σRs consist of sigma receptor one (σ1R) and sigma receptor two (σ2R) and are expressed in numerous regions of the brain. The sigma receptor was originally proposed as a subtype of opioid receptors and was suggested to contribute to the delusions and psychoses induced by benzomorphans such as SKF-10047 and pentazocine. Later studies confirmed that σRs are non-opioid receptors (not an µ opioid receptor) and play a more diverse role in intracellular signaling, apoptosis and metabolic regulation. σ1Rs are intracellular receptors acting as chaperone proteins that modulate Ca2+ signaling through the IP3 receptor. They dynamically translocate inside cells, hence are transmembrane proteins. The σ1R receptor, at the mitochondrial-associated endoplasmic reticulum membrane, is responsible for mitochondrial metabolic regulation and promotes mitochondrial energy depletion and apoptosis. Studies have demonstrated that they play a role as a modulator of ion channels (K+ channels; N-methyl-d-aspartate receptors [NMDAR]; inositol 1,3,5 triphosphate receptors) and regulate lipid transport and metabolism, neuritogenesis, cellular differentiation and myelination in the brain. σ1R modulation of Ca2+ release, modulation of cardiac myocyte contractility and may have links to G-proteins. It has been proposed that σ1Rs are intracellular signal transduction amplifiers. This review of the literature examines the mechanism of action of the σRs, their interaction with neurotransmitters, pharmacology, location and adverse effects mediated through them.

This chapter discusses organ-specific pathology. This chapter contains a detailed introduction to the field of toxicologic pathology, including fundamental concepts, description of the practice of general toxicologic pathology, and a review of selected topics in the field. It also contains brief overview of organ-specific toxicologic pathology addressing the toxicologic pathology of the respiratory tract; skin; gastrointestinal tract; liver; pancreas; kidney; lower urinary tract; cardiovascular system; bones and joints; eyes; immune system; hematopoietic system; endocrine system; male and female reproductive tract; and the embryo and fetus. Toxicologic pathology integrates the disciplines of pathology and toxicology. The effect of unintentional exposure to xenobiotics necessitates identification and description of the structural and functional adverse effects caused by these compounds for diagnostic purposes and to enable prediction of the likelihood of these adverse effects following such unintentional exposure. Toxicologic pathology can be defined as the study of the molecular, cellular, tissue, and organ response of the living organism when exposed to injurious agents or deprivations.

Toxicologic pathologists employ animal models to help understand and predict responses in humans, in terms of toxic and pharmacologic effects in particular. This use remains both the major tool for biomedical advances and a frequent source of significant controversy. Application of statistics to data sets from toxicologic pathology studies involves hypothesis testing, model fitting, and reduction of dimensionality. This chapter reviews statistical approaches to processing and analyzing data (i.e., descriptive statistics, confidence intervals, parametric and non-parametric methods, multiple range tests, handling of outliers) as well as specific applications (e.g., Bayesian statistics) and other experimental design and statistical methods. A set of decision trees is included to assist in choosing the appropriate methods for specific study designs. These analyses are used to establish the statistical nature and probe the biological relevance of the data being generated, and also to design and analyze experiments accordingly.

Toxicologic pathologists are essential to maintaining human, animal, and environmental health in modern societies. Their expertise in integrating morphological, molecular, and mechanistic data permits them to discern a subject's individual health or treatment group's collective susceptibility following exposure to novel materials. Their broad understanding of comparative biology, pathology, and toxicology makes them adept at translating animal data to identify hazards, assess safety, and manage potential risks. Thus, toxicologic pathologists are well suited to play many pivotal roles in discovering and developing new products to promote health, prevent disease, and improve the quality of individual and communal life.

Haschek and Rousseaux's Handbook of Toxicologic Pathology is a key reference on the integration of structure and functional changes in tissues associated with the response to pharmaceuticals, chemicals and biologics. The 3e has been expanded by a full volume, and covers aspects of safety assessment not discussed in the 2e. Completely revised with many new chapters, it remains the most authoritative reference on toxicologic pathology for scientists and researchers studying and making decisions on drugs, biologics, medical devices and other chemicals, including agrochemicals and environmental contaminants. New topics include safety assessment, the drug life cycle, risk assessment, communication and management, carcinogenicity assessment, pharmacology and pharmacokinetics, biomarkers in toxicologic pathology, quality assurance, peer review, agrochemicals, nanotechnology, food and toxicologic pathology, the environment and toxicologic pathology and more. It provides new chapters and in-depth discussion of timely topics in the area of toxicologic pathology and broadens the scope of the audience to include toxicologists and pathologists working in a variety of settings. It offers high-quality and trusted content in a multi-contributed work written by leading international authorities in all areas of toxicologic pathology. It features hundreds of full color images in both the print and electronic versions of the book to highlight difficult concepts with clear illustrations.

The pathologist is a vital partner in a team of pharmaceutical scientists in assuring that only safe and potentially efficacious new drug candidates are administered to human subjects. Pathologists play a key role in the selection and testing of new drug candidates, in decisions of whether to pursue or terminate research programs, in defining the potential hazards associated with new chemical entities (NCE), in defining how those hazards can be monitored in human subjects, and in translating those hazards into human risk assessments and the benefit : risk analyses critical to drug approval. While classically trained in disease diagnosis, pharmaceutical pathologists draw on their knowledge of the normal biology and morphology of body tissues and organs and their understanding of how these tissues can become perturbed during insult from disease, vascular disturbances, or toxins. Interpreting when tissue changes occur with respect to dose and systemic exposure and the reversibility of these changes is vital in defining margins between efficacious and toxic outcomes. While the pathologist is most critical in the description and interpretation of tissue damage during toxicology and carcinogenicity studies, the pathologist can also contribute to the entire preclinical development program for pharmaceutical candidates. These roles are briefly summarized in this chapter.

In the first half of the 20th century, congenital malformations were believed to arise in nature from genetic or infectious causes. The thalidomide tragedy of the late 1950s and early 1960s showed that assumption to be incorrect, and as such sensitized both the biomedical community and the public to the potential hazards of exposing the developing conceptus to foreign substances. In retrospect, realization that xenobiotic exposures and chemical imbalances were capable of affecting embryonic and fetal growth should not have been surprising to members of the medical, veterinary, and general scientific communities. Epidemiological data indicate that in utero exposure to many xenobiotics can result in structural defects and/or functional deficits within progeny. Humans and animals are exposed to numerous agents (e.g., drugs, environmental contaminants, metabolic by products) during critical periods of development, and at least some of these agents have the capacity to act as teratogens. Accordingly, a more thorough grasp of the processes that drive both normal and abnormal development has assumed increasing importance. This chapter will describe normal developmental events in selected vertebrate species, detail methods for determining if and how much such processes may have been disrupted by teratogens, and describe common mechanisms of maldevelopment along with factors that may influence the extent and severity of such damage.